Provenance Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

Provenance Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.39K	Hold	150	–	–	﹤0.01%	358
2025 Q4	$3.88K	Hold	150	–	–	﹤0.01%	350
2025 Q3	$3.87K	Hold	150	–	–	﹤0.01%	365
2025 Q2	$3.58K	Hold	150	–	–	﹤0.01%	359
2025 Q1	$3.73K	Hold	150	–	–	﹤0.01%	367
2024 Q4	$2.83K	Hold	150	–	–	﹤0.01%	401
2024 Q3	$2.26K	Hold	150	–	–	﹤0.01%	449
2024 Q2	$4.29K	Hold	150	–	–	﹤0.01%	331
2024 Q1	$4.38K	Hold	150	–	–	﹤0.01%	360
2023 Q4	$5.06K	Hold	150	–	–	﹤0.01%	362
2023 Q3	$4.6K	Buy	+150	New	+$5.41K	﹤0.01%	275

Other funds holding PCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return